Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: Relationship to cervical intraepithelial neoplasia

被引:118
作者
Nakagawa, M
Stites, DP
Farhat, S
Sisler, JR
Moss, B
Kong, F
Moscicki, AB
Palefsky, JM
机构
[1] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PEDIAT,SAN FRANCISCO,CA 94143
[2] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT STOMATOL,SAN FRANCISCO,CA 94143
[3] UNIV CALIF SAN FRANCISCO,SCH DENT,SAN FRANCISCO,CA 94143
[4] NIAID,VIRAL DIS LAB,BETHESDA,MD 20892
关键词
D O I
10.1086/513992
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cytotoxic T lymphocyte (CTL) responses to the human papillomavirus (HPV) type 16 E6 and E7 proteins were measured in 20 women with known HPV and cervical disease status, CTL assays were performed after stimulation with E6 or E7 fusion proteins using autologous B lymphoblastoid cells infected with vaccinia viruses expressing E6 or E7, CTL responses to E6 and E7 were detected in 6 (75%) of 8 and 5 (56%) of 9 HPV-16-positive women without cervical intraepithelial neoplasia (CIN), respectively, Responses to E6 or E7 were each detected in only 2 (29%) of 7 HPV-16-positive women with CIN. Responses to both antigens were found in 63% of women without CIN and 14% of those with CIN. CTL responses to E6 or E7 are more commonly detectable in HPV-16-positive women without CIN than in HPV-16-positive women with CIN, suggesting that CTL response may play a role in disease protection.
引用
收藏
页码:927 / 931
页数:5
相关论文
共 16 条
[1]  
CHEN L, 1992, J IMMUNOL, V148, P2617
[2]   HUMAN PAPILLOMAVIRUS TYPE-16 NUCLEOPROTEIN-E7 IS A TUMOR REJECTION ANTIGEN [J].
CHEN, LP ;
THOMAS, EK ;
HU, SL ;
HELLSTROM, I ;
HELLSTROM, KE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (01) :110-114
[3]  
EARL PL, 1991, CURRENT PROTOCOLS MO, V2
[4]   VACCINATION WITH CYTOTOXIC T-LYMPHOCYTE EPITOPE-CONTAINING PEPTIDE PROTECTS AGAINST A TUMOR-INDUCED BY HUMAN PAPILLOMAVIRUS TYPE-16-TRANSFORMED CELLS [J].
FELTKAMP, MCW ;
SMITS, HL ;
VIERBOOM, MPM ;
MINNAAR, RP ;
DEJONGH, BM ;
DRIJFHOUT, JW ;
TERSCHEGGET, J ;
MELIEF, CJM ;
KAST, WM .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (09) :2242-2249
[5]   HUMAN-LEUKOCYTE ANTIGEN-A2.1 RESTRICTED CANDIDATE CYTOTOXIC T-LYMPHOCYTE EPITOPES OF HUMAN PAPILLOMAVIRUS TYPE-16 E6-PROTEIN AND E7-PROTEIN IDENTIFIED BY USING THE PROCESSING-DEFECTIVE HUMAN CELL LINE-T2 [J].
KAST, WM ;
BRANDT, RMP ;
DRIJFHOUT, JW ;
MELIEF, CJM .
JOURNAL OF IMMUNOTHERAPY, 1993, 14 (02) :115-120
[6]   IMMUNIZATION AGAINST HUMAN PAPILLOMAVIRUS TYPE-16 TUMOR-CELLS WITH RECOMBINANT VACCINIA VIRUSES EXPRESSING E6 AND E7 [J].
MENEGUZZI, G ;
CERNI, C ;
KIENY, MP ;
LATHE, R .
VIROLOGY, 1991, 181 (01) :62-69
[7]  
MOSCICKI AB, 1993, OBSTET GYNECOL, V82, P578
[8]   T-cell proliferative response to human papillomavirus type 16 peptides: Relationship to cervical intraepithelial neoplasia [J].
Nakagawa, M ;
Stites, DP ;
Farhat, S ;
Judd, A ;
Moscicki, AB ;
Canchola, AJ ;
Hilton, JF ;
Palefsky, JM .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1996, 3 (02) :205-210
[9]   SEROLOGIC RESPONSE TO HUMAN PAPILLOMAVIRUS TYPE-16 (HPV-16) VIRUS-LIKE PARTICLES IN HPV-16 DNA-POSITIVE INVASIVE CERVICAL-CANCER AND CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE-III PATIENTS AND CONTROLS FROM COLOMBIA AND SPAIN [J].
NONNENMACHER, B ;
HUBBERT, NL ;
KIRNBAUER, R ;
SHAH, KV ;
MUNOZ, N ;
BOSCH, FX ;
DESANJOSE, S ;
VISCIDI, R ;
LOWY, DR ;
SCHILLER, JT .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (01) :19-24
[10]  
PALEFSKY JM, 1995, CANCER EPIDEM BIOMAR, V4, P415